Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib Plus Anti-PD-1/L1 Maintenance in ES-SCLC
NCT05509699Phase 2Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Sep 2022
- Primary completion
- Jul 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in small cell lung cancer (SCLC), sponsored by Hutchison MediPharma (HMP). Started Sep 2022; status: completed.
02
Drugs
surufatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05509699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509699.